Clinical Updates & Insights

Share

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
212 Clinical Updates found
AACR 2025 Research Roundup: Highlights of MSK’s Advances in Oncology Research
AACR 2025 Research Roundup: Highlights of MSK’s Advances in Oncology Research

Memorial Sloan Kettering Cancer Center (MSK) experts presented their latest advances in oncology research at the American Association for Cancer Research (AACR) Annual Meeting 2025, held April 25 to 30 in Chicago.
Secondary Rectal Cancer After Radiotherapy for Prostate Cancer Differs From Primary Rectal Cancer
Secondary Rectal Cancer After Radiotherapy for Prostate Cancer Differs From Primary Rectal Cancer

Patients with secondary rectal cancer after radiotherapy for prostate cancer have shorter survival compared with matched treatment-naïve patients. However, a new study by investigators at MSK has found distinct differences in patient characteristics, available treatment options, and tumor biologic characteristics that may explain the gap.
Overcoming Challenges with CAR T Cell Therapy for Patients with Non-Hodgkin Lymphoma
Overcoming Challenges with CAR T Cell Therapy for Patients with Non-Hodgkin Lymphoma

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with relapsed or refractory non-Hodgkin lymphomas, profound immune suppression, and predicting the likelihood of treatment failure.
Clinical Trials of New Stereotactic Radiosurgery Strategies for Lung Cancer Brain Metastases
Clinical Trials of New Stereotactic Radiosurgery Strategies for Lung Cancer Brain Metastases

Stereotactic radiosurgery (SRS) is increasingly used to treat brain metastases. The technique uses advanced, computer-guided imaging to deliver a highly targeted and intense dose of photon radiation. Since the radiation dose conforms to the three-dimensional shape and size of the target lesion, there is minimal exposure to the rest of the brain and fewer side effects than with standard radiation techniques.
Clinicopathologic and Genomic Discoveries in Metastatic Lung Cancer Add to Default shortcuts
Clinicopathologic and Genomic Discoveries in Metastatic Lung Cancer

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) surveillance. However, if patients with a high risk of brain metastasis after surgical resection can be identified, surveillance and prophylactic treatment with CNS-directed therapies may improve outcomes.
New Targeted Therapy Strategies for Addressing Non-Small Cell Lung Cancer Metastatic Disease
New Targeted Therapy Strategies for Addressing Non-Small Cell Lung Cancer Metastatic Disease

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many t...
New Study Confirms Safety of Watch and Wait For Patients with Locally Advanced Rectal Cancer
New Study Confirms Safety of Watch and Wait For Patients with Locally Advanced Rectal Cancer

A newly published pooled analysis of the Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial and the CAO/ARO/AIO-12 trial by the Ger...
Sphincter-Sparing Surgery May Increase Recurrence Risk in Patients with Distal Rectal Cancer Ineligible for Watch and Wait
Sphincter-Sparing Surgery May Increase Recurrence Risk in Patients with Distal Rectal Cancer Ineligible for Watch and Wait

A retrospective study of patients with distal rectal cancer at Memorial Sloan Kettering Cancer Center (MSK) has found a higher rate of local recurrence after intersphincteric resection with handsewn coloanal anastomosis (ISR-CAA) than with abdominoperineal resection (APR) in patients without a clinical response to neoadjuvant therapy who underwent total mesorectal excision (TME).
Myeloma specialist and cellular therapist Dr. Saad Usmani, Chief of the Myeloma Service at MSK
Quadruplet Therapy Significantly Improved Outcomes in Transplant-Ineligible Myeloma

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal residual disease (MRD) responses compared to VRd alone in patients with newly diagnosed, transplant-ineligible multiple myeloma.
Clinical Update
Zenocutuzumab: A Novel Bispecific Antibody for NRG1 Fusion-Positive Pancreatic and Lung Cancers
Zenocutuzumab: A Novel Bispecific Antibody for NRG1 Fusion-Positive Pancreatic and Lung Cancers

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to zenocutuzumab (Bizengri®), the first approved systemic therapy for patients with advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) fusion and pancreatic adenocarcinoma harboring a (NRG1) fusion.